The Grey Zone: A Review of the Management of B3 Lesions of the Breast
DOI:
https://doi.org/10.48111/2021.02.09Keywords:
B3 lesions, Breast Cancer, Indeterminate lesions, Core needle biopsy, uncertain malignant potential, Vacuum Assisted BiopsyAbstract
With the advent of widespread breast cancer screening programs along with raising public awareness, the number of patients presenting with B3 lesions on core biopsy has also increased. This grey zone consists of heterogeneous pathological entities with variable malignant potential, necessitating excision biopsy for full histological examination. This puts an additional burden on cost, theater time, and requiring invasive procedures on the patient. The term ‘malignant potential’ confers either an increased probability of finding concomitant cancer on excision biopsy or evolution towards in situ or invasive cancer over a period of time. The risk is not restricted to the breast where the biopsy or excision of the B3 lesion occurred, but anywhere in the same or contralateral breast. Because of management controversies, a multidisciplinary approach is the need of the hour to decrease the over or under-diagnosis, and over or under treatment. This review is aimed at giving an overview of the morphology and biological significance of B3 entities and current agreement on its management. It also focuses on the ways these internationally agreed protocols can be adopted in our resource-constrained country.
References
Ellis O, Humphreys S, Michell M, Pinder SE, Wells CA, Zakhour HD. Guidelines for non-operative diagnostic procedures and reporting in cancer screening. NHSBSP Publications. 2001;50:35–40.
Brian D Hayes, Cecily M Quinn. Pathology of B3 lesions of the breast. Diagnostic Histopathology. 2009;15(10):459-469.
Abdel-Fatah TM, Powe DG, Hodi Z, Reis-Filho JS, Lee AH, Ellis IO. Morphologic and molecular evolutionary pathways of low nuclear grade invasive breast cancers and their putative precursor lesions: further evidence to support the concept of low nuclear grade breast neoplasia family. Am J Surg Pathol. 2008;32(4):513–23.
El-Sayed ME, Rakha EA, Reed J, Lee AH, Evans AJ, Ellis IO. Predictive value of needle core biopsy diagnoses of lesions of uncertain malignant potential (B3) in abnormalities detected by mammographic screening. Histopathology. 2008;53(6):650–7
Richter-Ehrenstein C, Maak K, Roger S, Ehrenstein T. Lesions of “uncertain malignant potential” in the breast (B3) identified with mammography screening. BMC Cancer. 2018;18(1):829
Bianchi S, Caini S, Renne G, Cassano E, Ambrogetti D, Cattani MG, et al. Positive predictive value for malignancy on surgical excision of breast lesions of uncertain malignant potential (B3) diagnosed by stereotactic vacuum-assisted needle core biopsy (VANCB): a large multi-institutional study in Italy. Breast. 2011;20(3):264–70.
Saladin C, Haueisen H, Kampmann G, Oelschlegel C, Seifert B, Rageth L, et al. Lesions with unclear malignant potential (B3) after minimally invasive breast biopsy: evaluation of vacuum
biopsies performed in Switzerland and recommended further management. Acta Radiol. 2016;57(7):815–21.
Mooney KL, Bassett LW, Apple SK. Upgrade rates of high-risk breast lesions diagnosed on core needle biopsy: a single institution experience and literature review. Mod Pathol. 2016;29(12):1471–84
Rakha EA, Ahmed MA, Aleskandarany MA, Hodi Z, Lee AH, Pinder SE, et al. Diagnostic concordance of breast pathologists: lessons from the National Health Service Breast Screening Programme Pathology External Quality Assurance Scheme. Histopathology. 2017;70(4):632–42.
Nguyen CV, Albarracin CT, Whitman GJ, Lopez A, Sneige N. Atypical ductal hyperplasia in directional vacuum-assisted biopsy of breast microcalcifications: considerations for surgical excision. Ann Surg Oncol. 2011;18(3):752–61
Strachan C, Horgan K, Millican-Slater RA, Shaaban AM, Sharma N. Outcome of a new patient pathway for managing B3 breast lesions by vacuum-assisted biopsy: time to change current UK practice? J Clin Pathol. 2016;69(3):248–254
Renshaw AA, Gould EW. Long term clinical follow-up of atypical ductal hyperplasia and lobular carcinoma in situ in breast core needle biopsies. Pathology. 2016;48(1):25–29
Houssami N, Ciatto S, Ellis I, Ambrogetti D. Underestimation of malignancy of breast core-needle biopsy: concepts and precise overall and category-specific estimates. Cancer. 2007;109(3):487–495
Forester ND , Lowes S, Mitchell E ,Twiddy M. High risk (B3) breast lesions: What is the incidence of malignancy for individual lesion subtypes? A systematic review and meta-analysis. EJSO. 2019;45:519-527
Rageth CJ, O’Flynn EAM, Pinker K, Kubik-Huch RA, Mundinger A, Decker T, et al. Second International Consensus Conference on lesions of uncertain malignant potential in the breast(B3 lesions). Breast cancer research and treatment. 2018
Lucioni M, Rossi C, Lomoro P, Ballati F,Fanizza M, Ferrari A, Garcia-Etienne CA, Boveri E, Meloni G, Sommaruga MG, Ferraris E, Lasagna A, Bonzano E, Paulli M, Sgarella A, Di Giulio. Positive predictive value for malignancy of uncertain malignant potential (B3) breast lesions diagnosed on vacuum-assisted biopsy (VAB): is surgical excision still recommended? G.Eur Radiol. 2021 Feb;31(2):920-927.
Santucci D,Faiella E, Calabrese A, Favale L ,Zobel BB, Carlo de Felice. Our Radiological Experience on B3 Lesions: Correlation Between Mammographic and MRI Findings With Histologic Definitive Result. Clin Breast Cancer. 2019;19(5):643-e653.
Hoffmann.O,Stamatis GA,Bittner AK,Arnold J,Schnabel R,Krüger K,Kimmig R, Heubner M. B3-lesions of the breast and cancer risk - an analysis of mammography screening of patients. Mol Clin Oncol. 2016; 4(5): 705–708.
Pinder SE, Shaaban A, Deb R, Desai A, Gandhi A, Lee AHS, et al. NHS Breast Screening multidisciplinary working group guidelines for the diagnosis and management of breast lesions of uncertain malignant potential on core biopsy (B3 lesions). Clin Radiol. 2018;73(8):682–692
Pinder SE and Reis?Filho JS. Non?operative breast pathology: columnar cell lesions. J Clin Pathol. 2007; 60(12): 1307–1312.
Perry N, Broeders M, de Wolf C, Törnberg S, Holland R, von Karsa L (eds) European guidelines for quality assurance in breast cancer screening and diagnosis. Fourth edition/ Supplements. European Commission, Office for Official Publications of the European Union, Luxembourg, 73–120
Dabbs DJ, Schnitt SJ, Geyer FC, Weigelt B, Baehner FL, Decker T, Eusebi V, Fox SB, Ichihara S, Lakhani SR et al (2013) Lobular neoplasia of the breast revisited with emphasis on the role of E-cadherin immunohistochemistry. Am J Surg Pathol. 2013;37(7):1-11
Fisher ER, Land SR, Fisher B, Mamounas E, Gilarski L, Wolmark N. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: twelve-year observations concerning lobular carcinoma in situ. Cancer.2004;100(2):238–244
Chuba PJ, Hamre MR, Yap J, Severson RK, Lucas D, Shamsa F, Aref A. Bilateral risk for subsequent breast cancer after lobular carcinoma-in-situ: analysis of surveillance, epidemiology, and end results data. J Clin Oncol 2005;23(24):5534–5541
I O Ellis, S Humphreys, M Michell, S E Pinder, C A Wells, H D Zakhour. Guidelines for breast needle core biopsy handling and reporting in breast screening assessment. J Clin Pathol 2004;57:897–902.
Mayer S, Kayser G, Rucker G, Bogner D, Hirschfeld M, Hug C, et al. Absence of epithelial atypia in B3-lesions of the breast is associated with decreased risk for malignancy. Breast. 2017;31: 144–9.
Y. Y. Huang,H. Park, S. McLaren, P. Thirunavukkarasu, J. T. W. Lin, R. Rajakaruna, R. Dhillon, A. K. Ponniah. B3 lesion upgrade rates in a tertiary Australian breast centre: a 8-year experience. ANZ journal of Surgery. 2020;90(12):2521-2526
Kalife ET, Lourenco AP, Baird GL, Wang Y Clinical and radiologic follow-up study for biopsy diagnosis of radial scar/radial sclerosing lesion without other atypia. Breast J. 2016;22(6):637–644.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Bushra Rehman, Huma Majeed Khan
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
